# Reverie Labs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/reverie-labs

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.reverielabs.com
- Total disclosed funding: $25M
- Latest round: Series A (Feb 3, 2021)
- Investors on record: 9

## About

Based in Massachusetts, US, and founded in 2017, Reverie Labs, which operates as a pharmaceutical company develops deep learning-based modeling, massive-scale computation, and genetic algorithms to engineer new medicines. The company was co-founded by Jonah Kallenbach and Ankit Gupta and is backed by investors including Ridgeback Capital, Y Combinator, First Round Capital, and Neo. In February 2024, Ginkgo Bioworks acquired Reverie Labs from First Round Capital, Neo, Y Combinator, Ruvento Ventures, and Soma Capital Management.

The company operates a drug discovery platform that uses computational chemistry and machine learning-technology to discover and develop kinase inhibitors. As of 2024, the company's product line has cancer-treating drugs such as RVL-101, RVL-1-2, and RVL-103, which are developed by partnering with other organizations such as Roche and Genentech

## Funding rounds

- Series A, Feb 3, 2021, $25M — First Round Capital, Y Combinator, Neo, Ridgeback Asset Management
- Seed, Mar 16, 2018 — Y Combinator, Ruvento Ventures, Soma Capital Management, Uncommon Denominator, UpHonest Capital, South Park Commons

## Investors

- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed, Series A
- Ruvento Ventures (https://capitalatlas.ai/funds/ruvento-ventures) — Seed
- Soma Capital Management (https://capitalatlas.ai/funds/soma-capital-management) — Seed
- Uncommon Denominator (https://capitalatlas.ai/funds/uncommon-denominator) — Seed
- UpHonest Capital (https://capitalatlas.ai/funds/uphonest-capital) — Seed
- South Park Commons (https://capitalatlas.ai/funds/south-park-commons) — Seed
- First Round Capital (https://capitalatlas.ai/funds/first-round-capital) — Series A
- Neo — Series A
- Ridgeback Asset Management — Series A